# Exelixis Inc. (EXEL) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $72.31, market value $17.6 billion.

## Valuation
- **P/E (trailing): 21.6×** (5-yr avg 25.2×, 3-yr avg 24.0×). Exelixis Inc. trades at 21.6× trailing earnings, close to its own five-year average of 25.2×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 16.9×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.29**. A PEG of 0.29 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 7.1×**. Each dollar of revenue is priced at 7.1×.
- **Price / book: 9.6×**. The shares trade at 9.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 16.6×**. Enterprise value is 16.6× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 6.6%** (5-yr avg 6.0%). Free cash flow equals 6.6% of the market value, in line with its five-year average of 6.0%. Above 5% is generally attractive.
- **Earnings yield: 4.6%**. The inverse of the P/E: 4.6% of the price is earned each year.

## Profitability
- **Operating margin: 40.2%**. 40.2% of revenue is left after running the business, an exceptional level.
- **Net margin: 33.7%**. 33.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 36.2%**. 36.2% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 47.2%**. Return on all capital, debt included, is 47.2%: comfortably above what that capital costs.
- **Return on assets: 31.1%**. Each dollar of assets produces 31.1% of profit.

## Growth
- **Revenue growth (1 yr): 7.0%** (3-yr 12.9%/yr, 5-yr 18.6%/yr). Revenue grew 7.0% over the last year, against 18.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 58.0%** (3-yr 70.6%/yr, 5-yr 51.4%/yr). Earnings per share rose 58.0%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 37.8%/yr**. Free cash flow has compounded at 37.8% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Exelixis Inc. holds more cash than debt.
- **Current ratio: 3.56** (quick 3.56). Current assets cover the next year's liabilities 3.56 times.
- **Altman Z-score: 18.83**. A Z-score of 18.83 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Exelixis Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (14 analysts). 14 analysts cover Exelixis Inc.; the consensus is buy, with an average price target of $59.79 (-17% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 81.4%** (YTD 60.0%, 3-mo 27.4%). The shares are up 81.4% over twelve months including dividends.
- **From 52-week high: -1.5%** (92.4% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 83**. An RSI of 83 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.53** (volatility 34%). Beta of 0.53 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EXEL · Page: https://foliofundamentals.com/stocks/exel

Not investment advice.